115 HR 2451 IH: Pell Grant Preservation and Expansion Act
U.S. House of Representatives
2017-05-16
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 2451IN THE HOUSE OF REPRESENTATIVESMay 16, 2017Mrs. Davis of California (for herself, Mr. Scott of Virginia, Mr. Richmond, Ms. Judy Chu of California, Ms. Michelle Lujan Grisham of New Mexico, Ms. Roybal-Allard, Mr. Kilmer, and Mr. Danny K. Davis of Illinois) introduced the following bill; which was referred to the Committee on Education and the Workforce, and in addition to the Committee on the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concernedA BILLTo improve the structure of the Federal Pell Grant program, and for other purposes.

 1.Short titleThis Act may be cited as the Pell Grant Preservation and Expansion Act. 2.FindingsCongress finds the following:
 (1)The United States needs individuals with the knowledge, skills, and abilities that enable them to thrive as educated citizens in society and successfully participate in an interconnected economy.
 (2)Investments in higher education through student aid such as the Federal Pell Grant program under section 401 of the Higher Education Act of 1965 (20 U.S.C. 1070a) help students and families reach, afford, and complete education and training opportunities beyond high school.
 (3)The Federal Pell Grant program is the largest source of federally funded grant aid for postsecondary education.
 (4)The Federal Pell Grant program allows millions of people of the United States to attend college and is especially vital to students of color. Three in 5 African American undergraduate students, and one-half of all Latino undergraduate students, rely on the Federal Pell Grant program.
 (5)The Federal Pell Grant program should continue to be a reliable source of funding for aspiring students, their families, and future generations that they can count on to be there for them when they seek higher education.
 (6)To stabilize Federal Pell Grant funding and ensure the grant will continue to serve millions of students now and in the future, the program should become a fully mandatory program that grows with inflation.
 (7)Protecting surplus funds, restoring prior eligibility cuts, and expanding access to underserved students will give millions of students and families the critical student aid support they need and deserve.
			3.Table of contents; references
 (a)Table of contentsThe table of contents of this Act is as follows:  Sec. 1. Short title. Sec. 2. Findings. Sec. 3. Table of contents; references. Sec. 4. Funding Federal Pell Grants through mandatory funding. Sec. 5. Restoring Federal Pell Grant eligibility for borrower defense. Sec. 6. Federal Pell Grant eligibility for DREAMer students. Sec. 7. Repeal of suspension of eligibility under the Higher Education Act of 1965 for grants, loans, and work assistance for drug-related offenses. Sec. 8. Extending Federal Pell Grant eligibility of certain short-term programs. Sec. 9. Providing Federal Pell grants for Iraq and Afghanistan veteran's dependents. Sec. 10. Increasing support for working students by 35 percent. Sec. 11. Increasing the Federal Pell Grant auto-zero threshold. Sec. 12. Raising the total semesters of Federal Pell Grant eligibility. Sec. 13. Conforming amendments. Sec. 14. Effective date. (b)ReferencesExcept as otherwise expressly provided, whenever in this Act an amendment or repeal is expressed in terms of an amendment to, or repeal of, a section or other provision, the reference shall be considered to be made to a section or other provision of the Higher Education Act of 1965 (20 U.S.C. 1001 et seq.).
			4.Funding Federal Pell Grants through mandatory funding
 (a)Mandatory funding; reinstating eligibility for incarcerated individualsSection 401 (20 U.S.C. 1070a) is amended— (1)in subsection (a)(1), by striking through fiscal year 2017;
 (2)in subsection (b)— (A)by striking paragraphs (1), (6), and (7);
 (B)by redesignating paragraph (8) as paragraph (7); (C)by striking subparagraph (A) of paragraph (2);
 (D)by redesignating subparagraph (B) of paragraph (2) as paragraph (2); (E)by inserting before paragraph (2) (as redesignated by subparagraph (D)) the following:

 (1)AmountThe amount of the Federal Pell Grant for a student eligible under this subpart shall be— (A)the maximum Federal Pell Grant described in paragraph (6); less
 (B)the amount equal to the amount determined to be the expected family contribution with respect to such student for such year.;
 (F)in paragraph (4), by striking maximum amount of a Federal Pell Grant award determined under paragraph (2)(A) and inserting maximum Federal Pell Grant described in paragraph (6); (G)in paragraph (5), by striking maximum amount of a Federal Pell Grant award determined under paragraph (2)(A) and inserting maximum amount of a Federal Pell Grant award described in paragraph (6);
 (H)by inserting after paragraph (5) the following:  (6)Maximum Federal Pell Grant (A)Award year 2018–2019For award year 2018–2019, the maximum Federal Pell Grant shall be $6,420.
 (B)Subsequent award yearsFor award year 2019–2020 and each subsequent award year, the maximum Federal Pell Grant shall be equal to the total maximum Federal Pell Grant for the preceding award year under this paragraph—
 (i)increased by the annual adjustment percentage for the award year for which the amount under this subparagraph is being determined; and
 (ii)rounded to the nearest $5. (C)Definition of annual adjustment percentageIn this paragraph, the term annual adjustment percentage, as applied to an award year, is equal to the estimated percentage increase in the Consumer Price Index (as determined by the Secretary, using the definition in section 478(f)) for the most recent calendar year ending prior to the beginning of that award year.; and
 (I)in paragraph (7), as redesignated by subparagraph (B), by striking may exceed and all that follows through the period and inserting may exceed the maximum Federal Pell Grant available for an award year.; (3)in subsection (f)—
 (A)in paragraph (1), by striking the matter preceding subparagraph (A) and inserting the following: After receiving an application for a Federal Pell Grant under this subpart, the Secretary (including any contractor of the Secretary processing applications for Federal Pell Grants under this subpart) shall, in a timely manner, furnish to the student financial aid administrator at each institution of higher education that a student awarded a Federal Pell Grant under this subpart is attending, the expected family contribution for each such student. Each such student financial administrator shall— ; and
 (B)in paragraph (3)— (i)by striking after academic year 1986–1987; and
 (ii)in paragraph (3), by striking the Committee on Appropriations of the Senate, the Committee on Appropriations of the House of Representatives, and;
 (4)by striking subsections (g) and (h); (5)by redesignating subsections (i) and (j) as subsections (g) and (h), respectively; and
 (6)by adding at the end the following:  (k)Appropriation of fundsThere are authorized to be appropriated, and there are appropriated, out of any money in the Treasury not otherwise appropriated, such sums as may be necessary for fiscal year 2017 and each subsequent fiscal year to provide the maximum Federal Pell Grant for which a student shall be eligible under this section during an award year..
 (b)Repeal of scoring requirementSection 406 of H. Con. Res. 95 (109th Congress) is amended— (1)by striking subsection (b); and
 (2)by striking (a) In general.—Upon and inserting the following: Upon. 5.Restoring Federal Pell Grant eligibility for borrower defenseSection 401(c)(5) (20 U.S.C. 1070a(c)(5)) is amended—
 (1)by striking (5) The period and inserting the following:  (5) Maximum period.—(A)In generalExcept as provided in subparagraph (B), the period; and (2)by adding at the end the following:

					(B)Exception
 (i)In generalAny Federal Pell Grant that a student received during a period described in subclause (I) or (II) of clause (ii) shall not count towards the student’s duration limits under this paragraph.
 (ii)Applicable periodsClause (i) shall apply with respect to any Federal Pell Grant awarded to a student to attend an institution—
 (I)during a period— (aa)for which the student received a loan under this title; and
 (bb)for which the loan described in item (aa) is forgiven under— (AA)section 437(c)(1) or 464(g)(1) due to the closing of the institution;
 (BB)section 455(h) due to the student’s successful assertion of a defense to repayment of the loan; or (CC)section 432(a)(6), section 685.215 of title 34, Code of Federal Regulations (or a successor regulation), or any other loan forgiveness provision or regulation under this Act, as a result of a determination by the Secretary or a court that the institution committed fraud or other misconduct; or
 (II)during a period for which the student did not receive a loan under this title but for which, if the student had received such a loan, the student would have qualified for loan forgiveness under subclause (I)(bb)..
 6.Federal Pell Grant eligibility for DREAMer studentsSection 484 (20 U.S.C. 1091) is amended— (1)in subsection (a)(5), by inserting , or be a Dreamer student, as defined in subsection (u) after becoming a citizen or permanent resident; and
 (2)by adding at the end the following:  (u)Dreamer students (1)In generalIn this section, the term Dreamer student means an individual who—
 (A)was younger than 16 years of age on the date on which the individual initially entered the United States;
 (B)has provided a list of each secondary school that the student attended in the United States; and (C) (i)has earned a high school diploma, the recognized equivalent of such diploma from a secondary school, or a high school equivalency diploma in the United States or is scheduled to complete the requirements for such a diploma or equivalent before the next academic year begins;
 (ii)has acquired a degree from an institution of higher education or has completed not less than 2 years in a program for a baccalaureate degree or higher degree at an institution of higher education in the United States and has made satisfactory academic progress, as defined in subsection (c), during such time period;
 (iii)at any time was eligible for a grant of deferred action under— (I)the June 15, 2012, memorandum from the Secretary of Homeland Security entitled Exercising Prosecutorial Discretion with Respect to Individuals Who Came to the United States as Children; or
 (II)the November 20, 2014, memorandum from the Secretary of Homeland Security entitled Exercising Prosecutorial Discretion with Respect to Individuals Who Came to the United States as Children and with Respect to Certain Individuals Who Are the Parents of U.S. Citizens or Permanent Residents; or
 (iv)has served in the uniformed services, as defined in section 101 of title 10, United States Code, for not less than 4 years and, if discharged, received an honorable discharge.
 (2)Hardship exceptionThe Secretary shall issue regulations that direct when the Department shall waive the requirement of subparagraph (A) or (B), or both, of paragraph (1) for an individual to qualify as a Dreamer student under such paragraph, if the individual—
 (A)demonstrates compelling circumstances for the inability to satisfy the requirement of such subparagraph (A) or (B), or both; and
 (B)satisfies the requirement of paragraph (1)(C).. 7.Repeal of suspension of eligibility under the Higher Education Act of 1965 for grants, loans, and work assistance for drug-related offenses (a)RepealSubsection (r) of section 484 (20 U.S.C. 1091(r)) is repealed.
 (b)Revision of FAFSA formSection 483 of the Higher Education Act of 1965 (20 U.S.C. 1090) is amended by adding at the end the following:

 (i)ConvictionsThe Secretary shall not include any question about the conviction of an applicant for the possession or sale of illegal drugs on the FAFSA (or any other form developed under subsection (a))..
 (c)Conforming amendmentsThe Act (20 U.S.C. 1001 et seq.) is amended— (1)in section 428(b)(3) (20 U.S.C. 1078(b)(3))—
 (A)in subparagraph (C), by striking 485(l) and inserting 485(k); and (B)in subparagraph (D), by striking 485(l) and inserting 485(k);
 (2)in section 435(d)(5) (20 U.S.C. 1085(d)(5))— (A)in subparagraph (E), by striking 485(l) and inserting 485(k); and
 (B)in subparagraph (F), by striking 485(l) and inserting 485(k); (3)in section 484 (20 U.S.C. 1091), as amended by section 6, by redesignating subsections (s),(t), and (u) as subsections (r), (s), and (t), respectively;
 (4)in section 485 (20 U.S.C. 1092)— (A)by striking subsection (k); and
 (B)by redesignating subsections (l) and (m) as subsections (k) and (l), respectively; and (5)in section 487(e)(2)(B)(ii)(IV) (20 U.S.C. 1094(e)(2)(B)(ii)(IV)), by striking (l) of section 485 and inserting (k) of section 485.
				8.Extending Federal Pell Grant eligibility of certain short-term programs
 (a)In generalSection 401 (20 U.S.C. 1070a), as amended by section 4, is further amended by inserting after subsection (h) the following:

					(i)Job training Federal Pell Grant program
 (1)DefinitionsIn this subsection: (A)Eligible career pathway programThe term eligible career pathway program means a program that—
 (i)meets the requirements of section 484(d)(2); (ii)is a program of training services listed under section 122(d) of the Workforce Innovation and Opportunity Act (29 U.S.C. 3152(d)); and
 (iii)is part of a career pathway, as defined in section 3 of such Act (29 U.S.C. 3102). (B)Job training programThe term job training program means a career and technical education program at an institution of higher education that—
 (i)provides not less than 150, and not more than 600, clock hours of instructional time over a period of not less than 8, and not more than 15, weeks;
 (ii)provides training aligned with the requirements of employers in the State or local area, which may include in-demand industry sectors or occupations, as defined in section 3 of the Workforce Innovation and Opportunity Act (29 U.S.C. 3102), in the State or local area (as defined in such section);
 (iii)is a program of training services, and provided through an eligible provider of training services, listed under section 122(d) of such Act (29 U.S.C. 3152(d));
 (iv)provides a student, upon completion of the program, with a recognized postsecondary credential, as defined in section 3 of such Act, that is recognized by employers in the relevant industry, including credentials recognized by industry or sector partnerships in the State or local area where the industry is located;
 (v)has been determined, by the institution of higher education, to provide academic content, an amount of instructional time, and a recognized postsecondary credential that are sufficient to—
 (I)meet the hiring requirements of potential employers; and (II)satisfy any applicable educational prerequisite requirement for professional licensure or certification, so that the student who completes the program and seeks employment qualifies to take any licensure or certification examination needed to practice or find employment in an occupation that the program prepares students to enter;
 (vi)may include integrated or basic skills courses; and (vii)may be offered as part of an eligible career pathway program.
 (2)In generalFor the award year beginning on July 1, 2018, and each subsequent award year, the Secretary shall carry out a program through which the Secretary shall award job training Federal Pell Grants to students in job training programs. Each job training Federal Pell Grant awarded under this subsection shall have the same terms and conditions, and be awarded in the same manner, as a Federal Pell Grant awarded under subsection (a), except as follows:
 (A)A student who is eligible to receive a job training Federal Pell Grant under this subsection is a student who—
 (i)has not yet attained a baccalaureate degree or postbaccalaureate degree; (ii)attends an institution of higher education;
 (iii)is enrolled, or accepted for enrollment, in a job training program at such institution of higher education; and
 (iv)meets all other eligibility requirements for a Federal Pell Grant (except with respect to the type of program of study, as provided in clause (iii)).
 (B)The amount of a job training Federal Pell Grant for an eligible student shall be determined under subsection (b)(1), except that—
 (i)the maximum Federal Pell Grant awarded under this subsection for an award year shall be 50 percent of the maximum Federal Pell Grant awarded under subsection (b)(5) applicable to that award year; and
 (ii)subsection (b)(4) shall not apply. (3)Inclusion in total eligibility periodAny period during which a student receives a job training Federal Pell Grant under this subsection shall be included in calculating the student's period of eligibility for Federal Pell Grants under subsection (c), and any regulations under such subsection regarding students who are enrolled in an undergraduate program on less than a full-time basis shall similarly apply to students who are enrolled in a job training program at an eligible institution on less than a full-time basis..
 (b)Additional safeguardsSection 496(a)(4) (20 U.S.C. 1099b(a)(4)) is amended— (1)in subparagraph (A), by striking and after the semicolon;
 (2)in subparagraph (B)(ii), by inserting and after the semicolon; and (3)by adding at the end the following:

 (C)if such agency or association has or seeks to include within its scope of recognition the evaluation of the quality of institutions of higher education participating in the job training Federal Pell Grant program under section 401(i), such agency or association shall, in addition to meeting the other requirements of this subpart, demonstrate to the Secretary that, with respect to such job training programs—
 (i)the agency or association’s standards include a process for determining whether the program provides training aligned with the requirements of employers in the State or local area served by the program; and
 (ii)the agency or association requires a demonstration that the program— (I)has identified each recognized postsecondary credential offered and the corresponding industry or sector partnership that actively recognizes each credential in the relevant industry in the State or local area where the industry is located; and
 (II)provides the academic content and amount of instructional time that is sufficient to— (aa)meet the hiring requirements of potential employers; and
 (bb)satisfy any applicable educational prerequisites for professional licensure or certification requirements so that the student who completes the program and seeks employment qualifies to take any licensure or certification examination that is needed to practice or find employment in an occupation that the program prepares students to enter;.
				9.Providing Federal Pell grants for Iraq and Afghanistan veteran's dependents
 (a)AmendmentsPart A of title IV (20 U.S.C. 1070a et seq.) is amended— (1)in section 401, as amended by section 8, by inserting after subsection (i) the following:

						(j)Scholarships for veteran's dependents
 (1)Definition of eligible veteran's dependentIn this subsection, the term eligible veteran's dependent means a dependent or an independent student— (A)whose parent or guardian was a member of the Armed Forces of the United States and died as a result of performing military service in Iraq or Afghanistan after September 11, 2001; and
 (B)who, at the time of the parent or guardian's death, was— (i)less than 24 years of age; or
 (ii)enrolled at an institution of higher education on a part-time or full-time basis. (2)Grants (A)In generalThe Secretary shall award a Federal Pell Grant, as modified in accordance with the requirements of this subsection, to each eligible veteran's dependent to assist in paying the eligible veteran's dependent's cost of attendance at an institution of higher education.
 (B)DesignationFederal Pell Grants made under this subsection may be known as Iraq and Afghanistan Service Grants. (3)Prevention of double benefitsNo eligible veteran's dependent may receive a grant under both this subsection and subsection (a).
 (4)Terms and conditionsThe Secretary shall award Iraq and Afghanistan Service Grants under this subsection in the same manner and with the same terms and conditions, including the length of the period of eligibility, as the Secretary awards Federal Pell Grants under subsection (a), except that—
 (A)the award rules and determination of need applicable to the calculation of Federal Pell Grants under subsection (a) shall not apply to Iraq and Afghanistan Service Grants;
 (B)the provisions of paragraph (1)(B) and (3) of subsection (b), and subsection (f), shall not apply; (C)the maximum period determined under subsection (c)(5) shall be determined by including all Iraq and Afghanistan Service Grants received by the eligible veteran's dependent, including such Grants received under subpart 10 before the effective date of this subsection; and
 (D)an Iraq and Afghanistan Service Grant to an eligible veteran's dependent for any award year shall equal the maximum Federal Pell Grant available under subsection (b)(5) for that award year, except that an Iraq and Afghanistan Service Grant—
 (i)shall not exceed the cost of attendance of the eligible veteran's dependent for that award year; and
 (ii)shall be adjusted to reflect the attendance by the eligible veteran's dependent on a less than full-time basis in the same manner as such adjustments are made for a Federal Pell Grant under subsection (a).
 (5)Estimated financial assistanceFor purposes of determinations of need under part F, an Iraq and Afghanistan Service Grant shall not be treated as estimated financial assistance as described in sections 471(3) and 480(j).; and
 (2)by striking subpart 10 of part A (20 U.S.C. 1070h). (b)Effective date; transition (1)Effective dateThe amendments made by this section shall take effect with respect to the award year immediately following the date of enactment of this Act.
 (2)TransitionThe Secretary shall take such steps as are necessary to transition from the Iraq and Afghanistan Service Grants program under subpart 10 of part A of title IV of the Higher Education Act of 1965 (20 U.S.C. 1070h), as in effect on the day before the effective date of this section, and the Iraq and Afghanistan Service Grants program under section 401(j) of the Higher Education Act of 1965 (20 U.S.C. 1070a(j)), as amended by this section.
				10.Increasing support for working students by 35 percent
 (a)Dependent studentsSection 475(g)(2)(D) (20 U.S.C. 1087oo(g)(2)(D)) is amended to read as follows:  (D)an income protection allowance (or a successor amount prescribed by the Secretary under section 478) of $9,010 for academic year 2018–2019;.
 (b)Independent students without dependents other than a spouseSection 476(b)(1)(A)(iv) (20 U.S.C. 1087pp(b)(1)(A)(iv)) is amended to read as follows:  (iv)an income protection allowance (or a successor amount prescribed by the Secretary under section 478)—
 (I)for single or separated students, or married students where both are enrolled pursuant to subsection (a)(2), of $14,010 for academic year 2018–2019; and
 (II)for married students where one is enrolled pursuant to subsection (a)(2), of $22,460 for academic year 2018–2019;.
 (c)Independent students with dependents other than a spouseSection 477(b)(4) (20 U.S.C. 1087qq(b)(4)) is amended to read as follows:  (4)Income protection allowanceThe income protection allowance is determined by the following table (or a successor table prescribed by the Secretary under section 478), for academic year 2018–2019:
						Income Protection Allowance

									Family SizeNumber in College
									(including student)12345For each additional subtract:

									2$35,470$29,410$6,030
									344,17038,130$32,070
									454,54045,49042,450$36,370
									564,36058,28052,24046,190$40,160
									675,26069,21063,19057,09051,070
									For each
									additional
									add:8,500.
 (d)Updated tables and amountsSection 478(b) (20 U.S.C. 1087rr(b)) is amended— (1)in paragraph (1), by striking subparagraphs (A) and (B) and inserting the following:

 (A)In generalFor each academic year after academic year 2018–2019, the Secretary shall publish in the Federal Register a revised table of income protection allowances for the purpose of sections 475(c)(4) and 477(b)(4), subject to subparagraphs (B) and (C).
 (B)Table for independent studentsFor each academic year after academic year 2018–2019, the Secretary shall develop the revised table of income protection allowances by increasing each of the dollar amounts contained in the table of income protection allowances under section 477(b)(4) by a percentage equal to the estimated percentage increase in the Consumer Price Index (as determined by the Secretary for the most recent calendar year ending prior to the beginning of the academic year for which the determination is being made), and rounding the result to the nearest $10.; and
 (2)in paragraph (2), by striking shall be developed and all that follows through the period at the end and inserting shall be developed for each academic year after academic year 2018–2019, by increasing each of the dollar amounts contained in such section for academic year 2018–2019 by a percentage equal to the estimated percentage increase in the Consumer Price Index (as determined by the Secretary for the most recent calendar year ending prior to the beginning of the academic year for which the determination is being made), and rounding the result to the nearest $10..
 11.Increasing the Federal Pell Grant auto-zero thresholdSection 479(c) (20 U.S.C. 1087ss(c)) is amended— (1)in paragraph (1)(B), by striking $23,000 and inserting $34,000;
 (2)in paragraph (2)(B), by striking $23,000 and inserting $34,000; and (3)in the matter following paragraph (2)(B), by striking adjusted according to increases in the Consumer Price Index, as defined in section 478(f) and inserting annually increased by the estimated percentage change in the Consumer Price Index, as defined in section 478(f), for the most recent calendar year ending prior to the beginning of an award year, and rounded to the nearest $1,000.
 12.Raising the total semesters of Federal Pell Grant eligibilitySection 401(c)(5)(A) (20 U.S.C. 1070a(c)(5)(A)), as amended by section 5, is further amended by striking 12 each place the term appears and inserting 14.
 13.Conforming amendmentsThe Act (20 U.S.C. 1001 et seq.) is amended— (1)in section 401A(d)(1)(B)(i) (20 U.S.C. 1070a–1(d)(1)(B)(i)), by striking section 401(b)(2)(B) and inserting section 401(b)(2);
 (2)in section 402D(d)(1) (20 U.S.C. 1070a–14(d)(1)), by striking section 401(b)(2)(A) and inserting section 401(b)(1); (3)in section 420R(d)(2) (20 U.S.C. 1070h(d)(2)), by striking subsection (b)(1), the matter following subsection (b)(2)(A)(v),;
 (4)in section 435(a)(5)(A)(i)(I) (20 U.S.C. 1085(a)(5)(A)(i)(I)), by striking under section 401(b)(2)(A) and inserting , as appropriate, under section 401(b)(2)(A) (as in effect on the day before the effective date of the Pell Grant Preservation and Expansion Act) or section 401(b)(1);
 (5)in section 483(e)(3)(A)(ii) (20 U.S.C. 1090(e)(3)(A)(ii)), by striking section 401(b)(2)(A) and inserting section 401(b)(1); (6)in section 485E(b)(1)(A) (20 U.S.C. 1092f(b)(1)(A)), by striking section 401(b)(2)(A) and inserting section 401(b)(1); and
 (7)in section 894(f)(2)(C)(ii)(I) (20 U.S.C. 1161y(f)(2)(C)(ii)(I)), by striking section 401(b)(2)(A) and inserting section 401(b)(1). 14.Effective dateExcept as otherwise provided, this Act, and the amendments made by this Act, shall take effect beginning on July 1, 2018, and shall apply to grant and award determinations made under title IV of the Higher Education Act of 1965 (20 U.S.C. 1001 et seq.) beginning with the 2018–2019 award year.


116 S4439 IS: Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020
U.S. Senate
2020-08-05
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II116th CONGRESS2d SessionS. 4439IN THE SENATE OF THE UNITED STATESAugust 5, 2020Ms. Smith (for herself, Mr. Merkley, Ms. Baldwin, Mrs. Gillibrand, and Ms. Harris) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILL To require any COVID–19 drug developed in whole or in part with Federal support to be affordable and accessible by prohibiting monopolies and price gouging, and for other purposes.1.Short titleThis Act may be cited as the Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020 or the MMAPPP Act of 2020.2.Requirements for licensing of new COVID–19 treatment and prevention technologies to meet domestic and global demand(a)Nonexclusive license requiredAny covered license granted by the Federal Government shall be an open, nonexclusive license.(b)Contractor, assignee, exclusive licenseeNotwithstanding any other provision of law, any contractor, assignee, or exclusive licensee to an invention developed in whole or in part in work performed under a covered transaction shall grant an open, non-exclusive license. If any such contractor, assignee, or exclusive licensee refuses to grant such license, the Federal Government shall grant the license.(c)Reasonable royalty(1)In generalExcept as provided in paragraph (4), an entity that accepts an open, nonexclusive license under this section shall pay a reasonable royalty with respect to sales within the United States to—(A)the holder of a patent that claims the COVID–19 related invention; or(B)the holder of an application approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of the Public Health Service Act (42 U.S.C. 262) for which any FDA-granted exclusivity with respect to a drug related to such invention that was terminated under this section.(2)RoyaltyThe reasonable royalty described under paragraph (1) shall be a percentage of sales of the entity paying the royalty, where the percentage rate is no higher than the average royalty rate estimated from the data provided by the Internal Revenue Service for pharmaceutical manufacturer Federal income tax returns.(3)Requirements(A)In generalThe royalty described under paragraph (2) shall be subject to the applicable royalty rate requirements of section 319B of the Public Health Service Act, as added by section 5 of this Act. (B)Multiple affected partiesIn the case of more than one recipient of a royalty, the royalty shall be divided among each such recipient (including any manufacturer) in a manner agreed upon by the manufacturer and other recipients, or, in the absence of such an agreement, in a manner the Secretary determines to be appropriate.(4)Exception for Government-owned inventionsAn entity that accepts an open, nonexclusive license for a federally owned invention described under section 207 of title 35, United States Code, is not required to pay a royalty under this section.(d)DefinitionsIn this section:(1)Covered licenseThe term covered license means a license that allows a licensee to make, use, offer to sell, or sell, export, or import into the United States or any other country or territory a COVID–19 related invention pursuant to—(A)section 207 of title 35, United States Code; and(B)section 12 of the Stevenson-Wydler Technology Innovation Act of 1980 (15 U.S.C. 3710a).(2)Covered transactionThe term covered transaction means any contract, funding agreement, license, other transaction, or other arrangement entered into between a party and the Federal Government on or after the date of enactment of this Act with respect to research and development regarding a drug that—(A)is intended or anticipated to be used to diagnose, mitigate, prevent, or treat COVID–19; and(B)consists of—(i)a licensing agreement pursuant to section 207 of title 35, United States Code;(ii)a cooperative research and development agreement and licensing agreement pursuant to section 12 of the Stevenson-Wydler Technology Innovation Act of 1980 (15 U.S.C. 3710a);(iii)a funding agreement, as defined under section 201 of title 35, United States Code; or(iv)any other transaction entered into pursuant to—(I)section 319L, 421, or 480 of the Public Health Service Act (42 U.S.C. 247d–7e, 285b–3, 287a);(II)section 105 of the National Institutes of Health Reform Act of 2006 (42 U.S.C. 284n); or(III)section 2371 of title 10, United States Code.(3)COVID–19 related inventionThe term COVID–19 related invention means any invention that claims a drug that is manufactured, used, designed, developed, modified, licensed, or procured to diagnose, mitigate, prevent, treat, or cure COVID–19; a use of such drug; a form of such drug; a method of use of such drug; or a method of manufacturing such drug.(4)FDA-granted exclusivityThe term FDA-granted exclusivity means prohibitions on the submission or approval of drug applications granted under any of the following:(A)Clauses (ii) through (v) of section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(c)(3)(E)).(B)Subsection (j)(5)(B)(iv) or clause (ii), (iii), or (iv) of subsection (j)(5)(F) of such Act (21 U.S.C. 355(c)(3)(E)).(C)Section 505A of such Act (21 U.S.C. 355a).(D)Section 505E of such Act (21 U.S.C. 355f).(E)Section 527 of such Act (21 U.S.C. 360cc).(F)Section 351(k)(7) of the Public Health Service Act (42 U.S.C. 262(k)(7)).(G)Any other provision of law that provides for marketing or data exclusivity (or extension of exclusivity) with respect to a drug.(5)Open, nonexclusive licenseThe term open, nonexclusive license means a license that allows a qualified licensee, subject to the provisions of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and the Public Health Service Act (42 U.S.C. 201 et seq.)—(A)to make, use, offer to sell, sell, export, or import into the United States and any other country and territory an invention;(B)to reference or rely upon earlier-submitted regulatory test data or the earlier grant of marketing approval of a treatment or vaccine related to such invention; and(C)to access and use otherwise confidential know-how relating to the manufacture of such invention.3.Requirements for reasonable pricing of federally supported COVID–19 drugs(a)Reasonable pricing requirementsAny covered transaction shall include terms and conditions requiring that the pricing of the drug by the party referred to in section 2(d)(2) be fair and reasonable, and facilitate global access, taking into consideration—(1)the impact of the price on access to the drug in the United States, taking into consideration racial disparities in COVID–19 cases and fatalities and other socioeconomic disparities;(2)the impact of the price on health program spending and budgets in the United States;(3)the risk adjusted value of Federal subsidies and investments related to the drug;(4)the costs associated with development and manufacturing of the drug;(5)the size of the affected patient population in the United States and globally; and(6)the therapeutic efficacy of the drug.(b)DefinitionsIn this section:(1)Covered transactionThe term covered transaction has the meaning given to such term in section 2.(2)DrugThe term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321). 4.Reporting on the expenditures of manufacturers with respect to COVID–19 drugs(a)Covered drugFor purposes of this section, the term covered drug means a drug that is intended or anticipated to be used to diagnose, mitigate, prevent, or treat COVID–19.(b)Reporting requiredThe manufacturer of a covered drug shall submit a report described in subsection (c) to the Secretary upon—(1)the submission of an application for approval of the drug under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355);(2)investigational use of the drug under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or section 351(a)(3) of the Public Health Service Act (42 U.S.C. 262(a)(3));(3)the submission of an application for licensing the drug under subsection (a) or (k) of section 351 of the Public Health Service Act (42 U.S.C. 262);(4)the issuance of an authorization for emergency use of the drug under section 564 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3); or(5)the marketing of the drug.(c)ContentsA report under subsection (a), consistent with the standard for disclosures described in section 213.3(d) of title 12, Code of Federal Regulations (as in effect on the date of enactment of this Act), shall address the expenditures of the manufacturer with respect to the covered drug and include, at a minimum—(1)the sponsor or sponsors of the covered drug;(2)the current wholesale acquisition cost of the covered drug when applicable;(3)the total expenditures of the manufacturer, specified by individual costs, on—(A)materials and manufacturing for the covered drug; and(B)acquiring patents and licensing for the covered drug;(4)the total amount and percentage of research and development expenditures for the covered drug that was derived from Federal funds;(5)the total amount of any Federal benefits received by the manufacturer with respect to the covered drug, including—(A)the specific amounts and periods of impact for each such benefit;(B)the specific value of any tax credits, including benefits from patient assistance programs and donated samples;(C)clinical and preclinical investments;(D)any Federal benefit toward manufacturing costs, including building or retrofitting facilities;(E)Federal grants, including from the National Institutes of Health, the Centers for Disease Control and Prevention, the Department of Defense, the Department of Energy, or other Federal departments or agencies;(F)patent applications that benefitted from such grants;(G)patent extensions;(H)exclusivity periods; and(I)waivers of fees;(6)the total expenditures of the manufacturer on research and development, itemized by basic and preclinical research and by clinical research, reported separately for each clinical trial, for the covered drug to demonstrate that the covered drug meets applicable statutory standards for approval under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), licensure under section 351 of the Public Health Service Act (42 U.S.C. 262), an exemption for investigational use under section 505(i) of the Federal Food, Drug, or Cosmetic Act (21 U.S.C. 355(i)) or section 351(a)(3) of the Public Health Service Act (42 U.S.C. 262(a)(3)), or authorization under section 564 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3), as applicable;(7)the total expenditures of the manufacturer on pursuing new or expanded indications or dosage changes for the covered drug under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of the Public Health Service Act (42 U.S.C. 262);(8)the total expenditures of the manufacturer on carrying out postmarket requirements related to such drug, including under section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(o)(3));(9)the specific expenditures associated with marketing and advertising costs for the covered drug;(10)any anticipated royalty fees from licensing to other manufacturers; and(11)with respect to the manufacturer—(A)all stock-based performance metrics used by the manufacturer to determine executive compensation over the preceding 12 months; and(B)any additional information the manufacturer chooses to provide related to drug pricing decisions.(d)Civil monetary penalties(1)Failure to submitAny manufacturer of a covered drug that fails to submit a report as required by this section, following notification by the Secretary to the manufacturer that the manufacturer is not in compliance with this section, shall be subject to a civil monetary penalty of $100,000 for each day on which the violation continues.(2)False informationAny manufacturer of a covered drug that knowingly provides false information in a report under this section is subject to a civil monetary penalty in an amount not to exceed $100,000 for each item of false information.(e)Public posting(1)In generalSubject to paragraph (3), the Secretary shall post each report submitted under subsection (b) on the public website of the Department of Health and Human Services no later than 30 days after the submission of the report.(2)FormatThe Secretary shall ensure that such reports are—(A)user-friendly to the public; and(B)written in plain language that consumers can readily understand.(3)Protected informationNothing in this section shall be construed to authorize the public disclosure of information submitted by a manufacturer that is prohibited from disclosure by any applicable law concerning the protection of trade secrets, commercial information, and other information.(f)DefinitionIn this section, the term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321). 5.Pricing requirements for existing treatments and vaccines in a public health emergencyTitle III of the Public Health Service Act is amended by inserting after section 319A (42 U.S.C. 247d–1) the following new section:319B.Pricing requirements for treatments and vaccines in a public health emergency(a)DefinitionsFor purposes of this section:(1)The term covered drug means a drug (including any vaccine) used to diagnose, mitigate, prevent, or treat a disease or disorder with respect to which there is or was in effect a declaration of a public health emergency under section 319.(2)The term covered period means the period ending if and when the circumstances which led to an applicable public health emergency cease to exist and are unlikely to recur.(3)The term FDA-granted exclusivity means prohibitions on the submission or approval of drug applications granted under any of the following:(A)Clauses (ii) through (v) of section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act.(B)Subsection (j)(5)(B)(iv) or clause (ii), (iii), or (iv) of subsection (j)(5)(F) of such Act.(C)Section 505A of such Act.(D)Section 505E of such Act.(E)Section 527 of such Act.(F)Section 351(k)(7) of this Act.(G)Any other provision of law that provides for marketing or data exclusivity (or extension of exclusivity) with respect to a drug.(4)The term wholesale acquisition cost has the meaning given that term in section 1847A(c)(6)(B) of the Social Security Act.(b)Determination of excessive priceDuring any covered period with respect to a covered drug, the Secretary shall determine that the price of a covered drug is excessive if the wholesale acquisition cost (or a more relevant measure of price) of the covered drug is not fair and reasonable, or does not facilitate global access, taking into consideration—(1)the impact of the price on access to the covered drug in the United States, taking into consideration racial disparities and other socioeconomic disparities;(2)the impact of the price on health program spending and budgets in the United States;(3)the risk adjusted value of Federal subsidies and investments related to the covered drug;(4)the costs associated with development and manufacturing of the covered drug;(5)the size of the affected patient population in the United States and globally; and(6)the therapeutic efficacy of the covered drug.(c)Excessive pricing remedyIf the Secretary determines pursuant to subsection (b) that the price of a covered drug is excessive, the Secretary—(1)shall waive or void any FDA-granted exclusivities with respect to the covered drug, effective on the date that the excessive price determination is made; and(2)shall grant open, nonexclusive licenses allowing any person to make, use, offer to sell, or sell, or import into the United States such drug, and to rely upon the regulatory test data of such drug, and to access and use otherwise confidential information, including know-how, related to the manufacture of such drug in accordance with subsection (d).(d)Reasonable royalty(1)In generalAn entity accepting an open, nonexclusive license under subsection (c)(2) shall pay a reasonable royalty with respect to sales within the United States to the holder of a patent that claims the covered drug or that claims a use of the covered drug or to the holder of an application approved under section 505 of the Federal Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act for which any FDA-granted exclusivity with respect to the covered drug was terminated under subsection (c)(1).(2)Royalty rateSuch royalty rate shall be—(A)a percentage of sales, where the percentage rate is no higher than the average royalty rate estimated from the data provided by the Internal Revenue Service for pharmaceutical manufacturer Federal income tax returns; or(B)an amount as determined by the Secretary, taking into account—(i)the therapeutic efficacy of the covered drug;(ii)the size of the affected patient population in the United States and globally;(iii)the risk adjusted value of Federal subsidies and investments related to the covered drug;(iv)the extent to which the manufacturer of the covered drug has recovered risk adjusted investments related to the covered drug, including the investments related to the invention, regulatory test data, and any other relevant research and development costs; and(v)any other information the Secretary determines appropriate.(3)Sales within other countriesAn entity accepting an open, nonexclusive license under subsection (c)(2) shall pay a reasonable royalty with respect to sales within other countries based on the royalty rate paid in the United States times the ratio between that country’s gross domestic product per capita divided by the United States gross domestic product per capita in the last year such data was available for both countries, but such royalty shall be due only if there are granted patents or data exclusivity rights in that country at the time of sale.(e)Requirements(1)In generalA royalty rate under subsection (d) shall be consistent with making the covered drug available to purchasers, including governmental and nongovernmental purchasers and individuals, at prices that are affordable and reasonable. Under no condition shall a royalty be set at a rate that would cause a covered drug for which an open, nonexclusive license was issued under subsection (c) to be sold at an excessive price, as determined under subsection (b).(2)Multiple affected partiesIn the case that there is one or more holders or investors in the patented inventions related to the covered drug, the royalty rate shall be divided among the holders or investors (including such manufacturer) in a manner agreed upon by the manufacturer and other holders or investors, or, in the absence of such an agreement, in a manner the Secretary determines to be appropriate.(3)PriceAn entity accepting an open, nonexclusive license under subsection (c)(2) shall sell the covered drug at a price not higher than the excessive price determined for the covered drug under subsection (b).(f)ClarificationAn open, nonexclusive license under subsection (c)(2) shall be liable, subject to adequate protection of the legitimate interests of any party utilizing the license, to be terminated only if the circumstances which led to the granting of the open, nonexclusive license cease to exist and are unlikely to recur. The Secretary may review, upon request, the continued existence of these circumstances..


116 HR 303 IH: Retired Pay Restoration Act
U.S. House of Representatives
2019-01-08
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I116th CONGRESS1st SessionH. R. 303IN THE HOUSE OF REPRESENTATIVESJanuary 8, 2019Mr. Bilirakis (for himself and Ms. Gabbard) introduced the following bill; which was referred to the Committee on Armed Services, and in addition to the Committee on Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo amend title 10, United States Code, to permit additional retired members of the Armed Forces who have a service-connected disability to receive both disability compensation from the Department of Veterans Affairs for their disability and either retired pay by reason of their years of military service or combat-related special compensation.
1.Short titleThis Act may be cited as the Retired Pay Restoration Act. 2.Findings and sense of Congress (a)FindingsCongress finds the following:
(1)For more than 100 years before 1999, all disabled military retirees were required to fund their own veterans’ disability compensation by forfeiting one dollar of earned retired pay for each dollar received in veterans’ disability compensation. (2)Since 1999, Congress has enacted legislation to progressively expand eligibility criteria for relief of the retired pay disability offset and reduce the burden of financial sacrifice on disabled military retirees.
(3)Absent adequate funding to eliminate the sacrifice for all disabled retirees, Congress has given initial priority to easing financial inequities for the most severely disabled and for combat-disabled retirees. (4)In the interest of maximizing eligibility within cost constraints, Congress effectively has authorized full concurrent receipt for all qualifying retirees with 100-percent disability ratings and all qualifying retirees with combat-related disability ratings, while phasing out the disability offset to retired pay over 10 years for retired members with noncombat-related, service-connected disability ratings of 50 percent to 90 percent.
(5)In pursuing these good-faith efforts, Congress acknowledges the regrettable necessity of creating new thresholds of eligibility that understandably are disappointing to disabled retirees who fall short of meeting those new thresholds. (6)Congress is not content with the status quo.
(b)Sense of CongressIt is the sense of Congress that military retired pay earned by service and sacrifice in defending the United States should not be reduced because a military retiree is also eligible for veterans’ disability compensation awarded for service-connected disability. 3.Eligibility for payment of both retired pay and veterans’ disability compensation for certain additional military retirees with compensable service-connected disabilities (a)Extension of Concurrent Receipt Authority to Retirees With Service-Connected Disabilities Rated Less Than 50 PercentSection 1414(a) of title 10, United States Code, is amended—
(1)by striking Compensation in the subsection heading and all that follows through Subject and inserting Compensation.—Subject; and (2)by striking paragraph (2).
(b)Amendments To reflect conclusion of Phase-In of Concurrent Receipt of Retired Pay and Veterans’ Disability CompensationSection 1414 of title 10, United States Code, is further amended— (1)in subsection (a), as amended by subsection (a) of this section, by striking the final sentence;
(2)by striking subsection (c) and redesignating subsections (d) and (e) as subsections (c) and (d), respectively; and (3)in subsection (d), as so redesignated, by striking paragraphs (3) and (4).
(c)Specification of qualified retirees for concurrent receipt purposesSection 1414 of title 10, United States Code, is further amended— (1)in subsection (a), as amended by subsections (a) and (b)—
(A)by striking a member or and all that follows through is entitled and inserting an individual who is a qualified retiree for any month is entitled; and (B)by inserting retired pay and veterans’ disability compensation after both;
(2)in subsection (b)— (A)by striking Special Rules in the subsection heading and all that follows through is subject to and inserting Special Rules for Chapter 61 Disability Retirees.—In the case of a qualified retiree who is retired under chapter 61 of this title, the retired pay of the member is subject to; and
(B)by striking paragraph (2); and (3)in subsection (d), as redesignated and amended by subsection (b), by adding at the end the following new paragraph:

(3)Qualified retireeThe term qualified retiree means a member or former member of the uniformed services who, with respect to any month— (A)is entitled to retired pay, other than in the case of a member retired under chapter 61 of this title with less than 20 years of service creditable under section 1405 of this title and less than 20 years of service computed under section 12732 of this title; and
(B)is entitled to veterans’ disability compensation.. (d)Clerical Amendments (1)Section headingThe heading of section 1414 of title 10, United States Code, is amended to read as follows:

1414.Members eligible for retired pay who are also eligible for veterans’ disability compensation: Concurrent payment of retired pay and disability compensation.
(2)Table of sectionsThe item relating to such section in the table of sections at the beginning of chapter 71 of title 10, United States Code, is amended to read as follows:   1414. Members eligible for retired pay who are also eligible for veterans’ disability compensation: Concurrent payment of retired pay and disability compensation.. (e)Conforming amendmentSection 1413a(f) of title 10, United States Code, is amended by striking Subsection (d) and inserting Subsection (c).
(f)Effective DateThe amendments made by this section shall take effect as of January 1, 2020, and shall apply to payments for months beginning on or after that date.


		II
		111th CONGRESS
		1st Session
		S. 2638
		IN THE SENATE OF THE UNITED STATES

			November 2, 2009
			Mr. Sessions introduced
			 the following bill; which was read twice and referred to the
			 Committee on
			 Finance

		A BILL
		To extend the temporary suspension of duty on
		  1,3,5-Triazine-2,4,6-triamine, N,N′′′-[1,2-ethanediylbis-[[[4,6-bis[butyl
		  (1,2,2,6,6-pentamethyl-4-piperidinyl)amino]-1,3,5-triazine-2-yl]imino]-3,1-propanediyl]]bis[N′,N′′-dibutyl-N′,N′′-bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-and
		  Butanedioic acid, dimethylester polymer with
		  4-hyroxy-2,2,6,6-tetramethyl-1-piperdine ethanol.

		1.1,3,5-Triazine-2,4,6-triamine,
			 N,N′′′-[1,2-ethanediylbis-[[[4,6-bis[butyl
			 (1,2,2,6,6-pentamethyl-4-piperidinyl)amino]-1,3,5-triazine-2-yl]imino]-3,1-propanediyl]]bis[N′,N′′-dibutyl-N′,N′′-bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-and
			 Butanedioic acid, dimethylester polymer with
			 4-hyroxy-2,2,6,6-tetramethyl-1-piperdine ethanol
			(a)In
			 generalHeading 9902.10.48 of the Harmonized Tariff Schedule of
			 the United States (relating to 1,3,5-Triazine-2,4,6-triamine,
			 N,N′′′-[1,2-ethanediylbis-[[[4,6-bis[butyl
			 (1,2,2,6,6-pentamethyl-4-piperidinyl)amino]-1,3,5-triazine-2-yl]imino]-3,1-propanediyl]]bis[N′,N′′-dibutyl-N′,N′′-bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-and
			 Butanedioic acid, dimethylester polymer with
			 4-hyroxy-2,2,6,6-tetramethyl-1-piperdine ethanol) is amended by striking
			 12/31/2009 and inserting 12/31/2011.
			(b)Effective
			 dateThe amendment made by subsection (a) applies to goods
			 entered, or withdrawn from warehouse for consumption, on or after the 15th day
			 after the date of the enactment of this Act.


		I
		111th CONGRESS
		1st Session
		H. R. 2275
		IN THE HOUSE OF REPRESENTATIVES

			May 6, 2009
			Mr. Jackson of
			 Illinois (for himself, Mr.
			 Crenshaw, and Mr. Castle)
			 introduced the following bill; which was referred to the
			 Committee on Energy and
			 Commerce

		A BILL
		To support research and public awareness activities with
		  respect to inflammatory bowel disease, and for other purposes.

		1.Short titleThis Act may be cited as the
			 Inflammatory Bowel Disease Research
			 and Awareness Act.
		2.FindingsThe Congress finds as follows:
			(1)Crohn’s disease
			 and ulcerative colitis are serious inflammatory diseases of the
			 gastrointestinal tract.
			(2)Crohn’s disease
			 may occur in any section of the gastrointestinal tract but is predominately
			 found in the lower part of the small intestine and the large intestine.
			 Ulcerative colitis is characterized by inflammation and ulceration of the
			 innermost lining of the colon. Complete removal of the colon in patients with
			 ulcerative colitis can potentially alleviate and cure symptoms.
			(3)Because Crohn’s
			 disease and ulcerative colitis behave similarly, they are collectively known as
			 inflammatory bowel disease. Both diseases present a variety of symptoms,
			 including severe diarrhea; abdominal pain with cramps; fever; arthritic joint
			 pain, inflammation of the eye, and rectal bleeding. There is no known cause of
			 inflammatory bowel disease, or medical cure.
			(4)It is estimated
			 that up to 1,400,000 people in the United States suffer from inflammatory bowel
			 disease, 30 percent of whom are diagnosed during their childhood years.
			(5)Children with
			 inflammatory bowel disease miss school activities because of bloody diarrhea
			 and abdominal pain, and many adults who had onset of inflammatory bowel disease
			 as children had delayed puberty and impaired growth and have never reached
			 their full genetic growth potential.
			(6)Inflammatory bowel
			 disease patients are at high risk for developing colorectal cancer.
			(7)The total annual
			 medical costs for inflammatory bowel disease patients are estimated at more
			 than $2,000,000,000.
			(8)The average time
			 from presentation of symptoms to diagnosis in children is three years.
			(9)Delayed diagnosis
			 of inflammatory bowel disease frequently results in more-active disease
			 associated with increased morbidity and complications.
			(10)The National
			 Institutes of Health National Commission on Digestive Diseases issued
			 comprehensive research goals related to inflammatory bowel disease in its April
			 2009 report to Congress and the American public entitled Opportunities
			 and Challenges in Digestive Diseases Research: Recommendations of the National
			 Commission on Digestive Diseases.
			3.Enhancing CDC’s
			 public health activities on inflammatory bowel diseasePart B of title III of the Public Health
			 Service Act (42 U.S.C. 243 et seq.) is amended by inserting after section 320A
			 the following:

				320B.Inflammatory
				bowel disease epidemiology research and pediatric patient registry
				program
					(a)In
				generalThe Secretary, acting through the Director of the Centers
				for Disease Control and Prevention, shall conduct, support, and expand
				epidemiology research on inflammatory bowel disease in both pediatric and adult
				populations and establish a registry of pediatric IBD patients.
					(b)Cooperative
				agreementIn carrying out subsection (a), the Secretary shall
				enter into a cooperative agreement with a nonprofit organization with expertise
				and experience in conducting inflammatory bowel disease research to develop and
				administer the epidemiology research and registry program, including—
						(1)expansion of
				existing IBD epidemiology program research activities within the National
				Center for Chronic Disease Prevention and Health Promotion; and
						(2)establishment,
				within one year of enactment of this section, of a population-based registry of
				pediatric IBD patients for the purposes of data collection, research, and
				patient services.
						(c)Pediatric IBD
				registry
						(1)FocusThe
				pediatric IBD registry established under this section shall focus on, but not
				be limited to, data collection, storage and analysis regarding—
							(A)the incidence and
				prevalence of pediatric IBD in the United States;
							(B)genetic and
				environmental factors associated with pediatric IBD;
							(C)age, race or
				ethnicity, gender, and family history of individuals diagnosed with pediatric
				IBD; and
							(D)treatment
				approaches and outcomes in pediatric IBD.
							(2)Additional
				requirementsIn establishing the pediatric IBD registry under
				this section, the Secretary shall—
							(A)identify,
				build-upon, and coordinate with existing public and private surveillance
				systems related to pediatric IBD; and
							(B)establish a secure
				communication mechanism within the registry to facilitate patient contact with
				researchers studying the environmental and genetic causes of pediatric IBD or
				conducting clinical trials on pediatric IBD.
							(d)DefinitionIn this section, the term IBD
				means inflammatory bowel disease.
					(e)Authorization of
				appropriationsTo carry out this section, there is authorized to
				be appropriated $3,500,000 for each of the fiscal years 2010 through
				2014.
					320C.Increasing
				public awareness of inflammatory bowel disease and improving health
				professional education
					(a)In
				generalThe Secretary, acting through the Director of the Centers
				for Disease Control and Prevention, shall award grants to eligible entities for
				the purpose of increasing awareness of inflammatory bowel disease among the
				general public and health care providers.
					(b)Use of
				fundsThe Secretary may not award a grant under this section to
				an eligible entity unless the entity agreed to use the grant to develop
				educational materials and conduct awareness programs focused on inflammatory
				bowel disease, including with respect to the following subjects:
						(1)Crohn’s disease
				and ulcerative colitis and their symptoms.
						(2)Testing required
				for appropriate diagnosis and the importance of accurate and early
				diagnosis.
						(3)Key differences
				between pediatric and adult disease.
						(4)Specific physical
				and psychosocial issues impacting pediatric patients, including stunted growth,
				malnutrition, delayed puberty, and depression.
						(5)Treatment options
				for both adult and pediatric patients.
						(6)The importance of
				identifying aggressive disease in children at an early stage in order to
				implement the most effective treatment protocol.
						(7)Complications of
				inflammatory bowel disease and related secondary conditions, including
				colorectal cancer.
						(8)Federal and
				private information resources for patients and physicians.
						(9)Incidence and
				prevalence data on pediatric and adult inflammatory bowel disease.
						(c)Report to
				CongressNot later than September 30, 2010, the Secretary shall
				report to the Committee on Energy and Commerce of the House of Representatives,
				the Committee on Health, Education, Labor, and Pensions of the Senate, and the
				Committees on Appropriations of the House of Representatives and the Senate
				regarding the status of activities under this section.
					(d)Eligible
				entityTo carry out this section, the term eligible
				entity means a nonprofit patient or professional organization with
				experience in serving adults and children with inflammatory bowel
				disease.
					(e)Authorization of
				appropriationsFor the purpose of carrying out this section,
				there is authorized to be appropriated $2,000,000 for each of fiscal years 2010
				through
				2014.
					.
		4.Sense of Congress
			 on expansion of biomedical research on inflammatory bowel diseaseIt is the sense of the Congress that—
			(1)the Secretary,
			 acting through the Director of the National Institutes of Health and the
			 Director of the National Institute of Diabetes and Digestive and Kidney
			 Diseases (in this section referred to as the Institute) should
			 aggressively support basic, translational, and clinical research designed to
			 meet the research goals for inflammatory bowel disease (in this section
			 referred to as IBD) included in the National Institutes of
			 Health National Commission on Digestive Diseases report entitled
			 Opportunities and Challenges in Digestive Diseases Research:
			 Recommendations of the National Commission on Digestive Diseases,
			 including by—
				(A)establishing an
			 objective basis for determining clinical diagnosis, detailed phenotype, and
			 disease activity in IBD;
				(B)developing an
			 individualized approach to IBD risk evaluation and management based on genetic
			 susceptibility;
				(C)modulating the
			 intestinal microflora to prevent or control IBD;
				(D)effectively
			 modulating the mucosal immune system to prevent or ameliorate IBD;
				(E)sustaining the
			 health of the mucosal surface;
				(F)promoting
			 regeneration and repair of injury in IBD;
				(G)providing
			 effective tools for clinical evaluation and intervention in IBD; and
				(H)ameliorating or
			 preventing adverse effects of IBD on growth and development in children and
			 adolescents;
				(2)the
			 Institute should support the training of qualified health professionals in
			 biomedical research focused on IBD, including pediatric investigators;
			 and
			(3)the Institute
			 should continue its strong collaboration with medical and patient organizations
			 concerned with IBD and seek opportunities to promote research identified in the
			 scientific agendas Challenges in Inflammatory Bowel Disease
			 Research (Crohn’s and Colitis Foundation of America) and Chronic
			 Inflammatory Bowel Disease (North American Society for Pediatric
			 Gastroenterology, Hepatology and Nutrition).
			5.Biennial
			 reportsSection 403(a)(5) of
			 the Public Health Service Act (42 U.S.C. 283(a)(5)) is amended—
			(1)by redesignating
			 subparagraph (L) as subparagraph (M); and
			(2)by inserting after
			 subparagraph (K) the following:

					(L)Inflammatory bowel
				disease.
					.


117 S1845 IS: Unwavering Support for our Coast Guard Act
U.S. Senate
2021-05-26
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II117th CONGRESS1st SessionS. 1845IN THE SENATE OF THE UNITED STATESMay 26, 2021Mr. Wicker introduced the following bill; which was read twice and referred to the Committee on Commerce, Science, and TransportationA BILLTo provide for pay and allowances for members of the Coast Guard during a funding gap, to provide full funding to address the shoreside facility maintenance and recapitalization backlog of the Coast Guard, and to diversify the Coast Guard, and for other purposes.1.Short titleThis Act may be cited as the Unwavering Support for our Coast Guard Act or the USCG Act.2.FindingsCongress makes the following findings:(1)The Coast Guard saves individuals in peril, thwarts illicit and coercive maritime activities, and fosters economic prosperity and environmental stewardship.(2)The Coast Guard is at all times a branch of the Armed Forces of the United States.(3)Additionally, the Coast Guard is a Federal law enforcement agency, a regulatory body, a first responder, and a member of the United States intelligence community.(4)With its unique mission set and authorities, the Coast Guard has a key role in addressing emerging national priorities in the United States and across the globe.(5)The Coast Guard is deployed worldwide. The white-hull diplomacy of the Coast Guard is essential to United States security.(6)Domestically, the Coast Guard keeps the waterways of the United States open and commerce moving smoothly by ensuring marine safety and maintaining aids to navigation.(7)Last year, the Coast Guard responded to 16,845 search and rescue cases and saved 4,286 lives.(8)The Coast Guard has admirably performed its missions with a fleet of aging vessels, aircraft, and facilities. The Coast Guard deserves Congress’s strong and full support for the recapitalization of its assets. 3.Pay and allowances for certain members of the Coast Guard during funding gap(a)In generalDuring a funding gap, the Secretary of the Treasury shall make available to the Secretary of Homeland Security, out of any amounts in the general fund of the Treasury not otherwise appropriated, such amounts as the Secretary of Homeland Security determines to be necessary to continue to provide, without interruption, pay and allowances to members of the Coast Guard, including reserve components thereof, who perform active service during the funding gap.(b)Funding gap definedIn this section, the term funding gap means any period after the beginning of a fiscal year for which interim or full-year appropriations for the personnel accounts of the Coast Guard have not been enacted.4.Full funding for shoreside facility maintenance and recapitalization(a)Statement of policyIt shall be the policy of the United States to provide, on the earliest date practicable, full funding to address the shoreside facility maintenance and recapitalization backlog of the Coast Guard.(b)Authorization of appropriationsThere is authorized to be appropriated to the Secretary of Homeland Security to eliminate the shoreside facility maintenance and recapitalization backlog of the Coast Guard $2,600,000,000 for fiscal years 2022 through 2030. 5.Fleet mix analysis(a)In generalThe Commandant of the Coast Guard (referred to in this Act as the Commandant) shall conduct an updated fleet mix analysis that provides for a fleet mix sufficient, as determined by the Commandant—(1)to carry out—(A)the missions of the Coast Guard; and(B)emerging mission requirements; and(2)to address—(A)national security threats; and (B)the global deployment of the Coast Guard to counter great power competitors.(b)ReportNot later than 1 year after the date of the enactment of this Act, the Commandant shall submit to Congress a report on the results of the updated fleet mix analysis required by subsection (a).6.Shore infrastructure investment plan(a)In generalThe Commandant shall develop an updated shore infrastructure investment plan that includes—(1)the construction of additional facilities to accommodate the updated fleet mix described in section 5(a);(2)improvements necessary to ensure that existing facilities meet requirements and remain operational for the lifespan of such fleet mix, including necessary improvements to information technology infrastructure; (3)a timeline for the construction and improvement of the facilities described in paragraphs (1) and (2); and(4)a cost estimate for construction and life-cycle support of such facilities, including for necessary personnel.(b)ReportNot later than 1 year after the date on which the report under section 5(b) is submitted, the Commandant shall submit to Congress a report on the plan required by subsection (a).7.Partnership program to diversify the Coast Guard(a)EstablishmentThe Commandant shall establish a program for the purpose of increasing the number of underrepresented minorities in the enlisted ranks of the Coast Guard.(b)PartnershipsIn carrying out the program established under subsection (a), the Commandant shall—(1)seek to enter into 1 or more partnerships with eligible entities—(A)to increase the visibility of Coast Guard careers;(B)to promote curriculum development—(i)to enable acceptance into the Coast Guard; and(ii)to improve success on relevant exams, such as the Armed Services Vocational Aptitude Battery; and(C)to provide mentoring for students entering and beginning Coast Guard careers; and (2)enter into a partnership with an existing Junior Reserve Officers' Training Corps for the purpose of promoting Coast Guard careers.(c)Eligible institution definedIn this section, the term eligible institution means—(1)an institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001));(2)an institution that provides a level of educational attainment that is less than a bachelor's degree; (3)a part B institution (as defined in section 322 of the Higher Education Act of 1965 (20 U.S.C. 1061)); (4)a Tribal College or University (as defined in section 316(b) of that Act (20 U.S.C. 1059c(b))); (5)a Hispanic-serving institution (as defined in section 502 of that Act (20 U.S.C. 1101a)); (6)an Alaska Native-serving institution or a Native Hawaiian-serving institution (as defined in section 317(b) of that Act (20 U.S.C. 1059d(b)));(7)a Predominantly Black institution (as defined in section 371(c) of that Act (20 U.S.C. 1071q(c)));(8)an Asian American and Native American Pacific Islander-serving institution (as defined in such section); and(9)a Native American-serving nontribal institution (as defined in such section). 8.Coast Guard yard resiliency(a)FindingsCongress makes the following findings:(1)For over a century, Coast Guard vessels have been built, repaired, and renovated in the Coast Guard Yard (referred to in this section as the Yard) in Baltimore, Maryland.(2)As 1 of only 5 remaining public shipyards in the United States, the Yard provides a unique capability to support the Coast Guard and the national fleet, including the National Oceanic and Atmospheric Administration, the Navy, the Army, and other Government agencies.(3)The Yard is an essential component of the core industrial base and fleet support operations of the Coast Guard, and its primary mission is to renovate, maintain, and repair Coast Guard vessels.(4)The Coast Guard is in the midst of recapitalizing its surface fleet by replacing smaller vessels with larger, more capable assets. Until recently, the Yard provided the Coast Guard with the organic capacity to service every vessel in the Coast Guard fleet, except polar icebreakers.(5)With the acquisition of the National Security Cutter and the projected acquisition of the Offshore Patrol Cutter, the Coast Guard will no longer have the organic capacity to service every vessel in the Coast Guard fleet.(b)Authorization of appropriationsThere is authorized to be appropriated to the Secretary of Homeland Security to improve the infrastructure of the Coast Guard public shipyard $350,000,000.


		I
		112th CONGRESS
		1st Session
		H. R. 605
		IN THE HOUSE OF REPRESENTATIVES

			February 10, 2011
			Mr. Paulsen (for
			 himself, Mr. Tiberi,
			 Mrs. Blackburn,
			 Mrs. McMorris Rodgers,
			 Mr. Kline,
			 Mr. Cravaack,
			 Mrs. Bachmann,
			 Mr. Bartlett,
			 Mr. Broun of Georgia,
			 Mr. Campbell,
			 Mr. Cole, Mr. Dent, Mrs.
			 Ellmers, Mr. Franks of
			 Arizona, Mr. Gibbs,
			 Ms. Granger,
			 Mr. Harris,
			 Mr. Jones,
			 Mr. Lamborn,
			 Mrs. Lummis,
			 Mr. Neugebauer,
			 Mr. Nugent,
			 Mr. Paul, Mr. Roe of Tennessee,
			 Mr. Sessions,
			 Mr. Walberg,
			 Mr. Walsh of Illinois,
			 Mr. Duncan of Tennessee,
			 Mr. Gardner,
			 Mr. Roskam,
			 Mr. Gerlach, and
			 Mr. Goodlatte) introduced the
			 following bill; which was referred to the Committee on Ways and Means

		A BILL
		To amend the Patient Protection and Affordable Care Act
		  to repeal certain limitations on health care benefits.

		1.Short titleThis Act may be cited as the
			 Patients' Freedom to Choose
			 Act.
		2.Repeal of
			 distributions for medicine qualified only if for prescribed drug or
			 insulinSection 9003 of the
			 Patient Protection and Affordable Care Act (Public Law 111–148) and the
			 amendments made by such section are repealed; and the Internal Revenue Code of
			 1986 shall be applied as if such section, and amendments, had never been
			 enacted.
		3.Repeal of
			 limitation on health flexible spending arrangements under cafeteria
			 plansSections 9005 and 10902
			 of the Patient Protection and Affordable Care Act (Public Law 111–148) and
			 section 1403 of the Health Care and Education Reconciliation Act of 2010
			 (Public Law 111–152) and the amendments made by such sections are
			 repealed.


116 HRES 293 EH: Providing for budget enforcement for fiscal year 2020.
U.S. House of Representatives
2019-04-09
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV
116th CONGRESS
1st Session
H. RES. 293
In the House of Representatives, U. S.,

April 9, 2019

RESOLUTION
Providing for budget enforcement for fiscal year 2020.

1.Budget matters
(a)Fiscal year 2020For the purpose of enforcing the Congressional Budget Act of 1974 for fiscal year 2020, the allocations, aggregates, and levels provided for in subsection (b) shall apply in the House of Representatives in the same manner as for a concurrent resolution on the budget for fiscal year 2020 with appropriate budgetary levels for fiscal year 2020 and for fiscal years 2021 through 2029.  (b)Committee allocations, aggregates, and levelsIn the House of Representatives, the chair of the Committee on the Budget shall submit a statement for publication in the Congressional Record as soon as practicable, containing—
(1)for the Committee on Appropriations, committee allocations for fiscal year 2020 for new discretionary budget authority of $1,295,018,000,000, and the outlays flowing therefrom, and committee allocations for fiscal year 2020 for current law mandatory budget authority and outlays, for the purpose of enforcing section 302 of the Congressional Budget Act of 1974;  (2)for all committees of the House other than the Committee on Appropriations, committee allocations for fiscal year 2020 and for the period of fiscal years 2020 through 2029 consistent with the most recent baseline of the Congressional Budget Office, as adjusted, to the extent practicable, for the budgetary effects of any provision of law enacted during the period beginning on the date such baseline is issued and ending on the date of submission of such statement, for the purpose of enforcing section 302 of the Congressional Budget Act of 1974;
(3)aggregate spending levels for fiscal year 2020 in accordance with the allocations established under paragraphs (1) and (2), for the purpose of enforcing section 311 of the Congressional Budget Act of 1974; and  (4)aggregate revenue levels for fiscal year 2020 and for the period of fiscal years 2020 through 2029 consistent with the most recent baseline of the Congressional Budget Office, as adjusted, to the extent practicable, for the budgetary effects of any provision of law enacted during the period beginning on the date such baseline is issued and ending on the date of submission of such statement, for the purpose of enforcing section 311 of the Congressional Budget Act of 1974.
(c)Additional matterThe statement referred to in subsection (b) may also include for fiscal year 2020, the matter contained in the provisions referred to in subsection (h).  (d)AdjustmentsThe chair of the Committee on the Budget of the House of Representatives may adjust the allocations, aggregates, and other budgetary levels included in the statement referred to in subsection (b)—
(1)to reflect changes resulting from the Congressional Budget Office’s updates to its baseline for fiscal years 2020 through 2029; or  (2)for any bill, joint resolution, amendment, or conference report by the amounts provided in such measure if such measure would not increase the deficit for either of the following time periods: fiscal year 2020 to fiscal year 2024 or fiscal year 2020 to fiscal year 2029.
(e)Overseas contingency operations/Global war on terrorism adjustment limitThe chair of the Committee on the Budget of the House of Representatives may adjust the allocations, aggregates, and other budgetary levels included in the statement referred to in subsection (b) in accordance with the Overseas Contingency Operations/Global War on Terrorism adjustment in section 251(b)(2)(A) of the Balanced Budget and Emergency Deficit Control Act of 1985 for any bill, joint resolution, amendment, or conference report, except that such adjustment shall not exceed $69,000,000,000 for the revised security category or $8,000,000,000 for the revised nonsecurity category.  (f)Adjustment for Internal Revenue Service tax enforcementThe chair of the Committee on the Budget of the House of Representatives may adjust the allocations, aggregates, and other budgetary levels included in the statement referred to in subsection (b) as follows:
(1)In generalIf a bill, joint resolution, amendment, or conference report making appropriations for fiscal year 2020 specifies an amount in the Enforcement account and the Operations Support account for tax enforcement activities, including tax compliance to address the Federal tax gap, of the Internal Revenue Service of the Department of the Treasury, then the adjustment shall be the additional new budget authority provided in such measure for such purpose, but shall not exceed $400,000,000.  (2)DefinitionAs used in this subsection, the term additional new budget authority means the amount provided for fiscal year 2020, in excess of $8,584,000,000, in a bill, joint resolution, amendment, or conference report and specified for tax enforcement activities, including tax compliance to address the Federal tax gap, of the Internal Revenue Service.
(g)Adjustment for the U.S. census for 2020The chair of the Committee on the Budget of the House of Representatives may adjust the allocations, aggregates, and other budgetary levels included in the statement referred to in subsection (b) as follows: (1)In generalIf a bill, joint resolution, amendment, or conference report making appropriations for fiscal year 2020 specifies an amount for the 2020 Census in the Periodic Censuses and Programs account of the Bureau of the Census of the Department of Commerce, then the adjustment shall be the new budget authority provided in such measure for such purpose, but shall not exceed $7,500,000,000.
(2)DefinitionAs used in this subsection, the term new budget authority means the amount provided for fiscal year 2020 in a bill, joint resolution, amendment, or conference report and specified to pay for expenses associated with 2020 Census operations.  (h)Application (1)Upon submission of the statement referred to in subsection (b), all references to allocations, aggregates, or other appropriate levels in this concurrent resolution in sections 5201, 5202, and 5203 of the House Concurrent Resolution 71 (115th Congress), specified in section 30104(f)(1) of the Bipartisan Budget Act of 2018, and continued in effect by section 103(m) of House Resolution 6 (116th Congress), shall be treated for all purposes in the House of Representatives as references to the allocations, aggregates, or other appropriate levels contained in the statement referred to in subsection (b), as adjusted in accordance with this section or any Act.
(2)The provisions of House Concurrent Resolution 71 (115th Congress), specified in section 30104(f)(1) of the Bipartisan Budget Act of 2018, shall have no force or effect through the remainder of the One Hundred Sixteenth Congress except for the sections of such concurrent resolution identified in paragraph (1).  (i)Adjustment for House passage of H.R. 2021Upon passage of H.R. 2021, the chair of the Committee on the Budget of the House of Representatives may adjust the allocations, aggregates, and other budgetary levels included in the statement referred to in subsection (b) consistent with H.R. 2021 as passed by the House.
2.Limitation on advance appropriations
(a)In generalExcept as provided in subsection (b), any general appropriation bill or bill or joint resolution continuing appropriations, or amendment thereto or conference report thereon, may not provide an advance appropriation.  (b)ExceptionsAn advance appropriation may be provided for programs, activities, or accounts identified in lists submitted for printing in the Congressional Record by the chair of the Committee on the Budget—
(1)for fiscal year 2021, under the heading Accounts Identified for Advance Appropriations in an aggregate amount not to exceed $28,852,000,000 in new budget authority, and for fiscal year 2022, accounts separately identified under the same heading; and  (2)for fiscal year 2021, under the heading Veterans Accounts Identified for Advance Appropriations in an aggregate amount not to exceed $87,636,650,000 in new budget authority.
(c)DefinitionThe term advance appropriation means any new discretionary budget authority provided in a general appropriation bill or bill or joint resolution continuing appropriations for fiscal year 2020, or any amendment thereto or conference report thereon, that first becomes available following fiscal year 2020.   Cheryl L. Johnson,Clerk.


114 HR 4252 IH: Foreclosure Relief and Extension for Servicemembers Act of 2015
U.S. House of Representatives

text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

		I
		114th CONGRESS
		1st Session
		H. R. 4252
		IN THE HOUSE OF REPRESENTATIVES

			December 15, 2015
			Mr. Fincher (for himself, Mr. Heck of Washington, and Mr. Stivers) introduced the following bill; which was referred to the Committee on Veterans' Affairs

		A BILL
		To extend temporarily the extended period of protection for members of uniformed services relating
			 to mortgages, mortgage foreclosure, and eviction, and for other purposes.

 1.Short titleThis Act may be cited as the Foreclosure Relief and Extension for Servicemembers Act of 2015. 2.Temporary Extension of Extended Period of Protections for Members of Uniformed Services Relating to Mortgages, Mortgage Foreclosure, and EvictionSection 710(d) of the Honoring America’s Veterans and Caring for Camp Lejeune Families Act of 2012 (Public Law 112–154; 50 U.S.C. 3953 note) is amended—(1)in paragraph (1), by striking December 31, 2015 and inserting December 31, 2017; and (2)in paragraph (3), by striking January 1, 2016 and inserting January 1, 2018.


		II
		112th CONGRESS
		2d Session
		S. 2341
		IN THE SENATE OF THE UNITED STATES

			April 24 (legislative
			 day, April 23), 2012
			Mr. Bennet (for himself
			 and Mr. Udall of Colorado) introduced the
			 following bill; which was read twice and referred to the
			 Committee on Energy and Natural
			 Resources

		A BILL
		To authorize the Secretary of Agriculture to accept the
		  quitclaim, disclaimer, and relinquishment of a railroad right-of-way within and
		  adjacent to Pike National Forest in El Paso County, Colorado.

		1.Acceptance of relinquishment
			 of railroad right-of-way by Manitou and Pikes Peak Railway Company, Colorado,
			 over National Forest System land
			(a)DefinitionsIn
			 this section:
				(1)CompanyThe
			 term Company means the Manitou and Pikes Peak Railway Company,
			 the successor in interest to the Mt. Manitou Park and Incline Railway
			 Company.
				(2)SecretaryThe
			 term Secretary means the Secretary of Agriculture.
				(b)Authority To
			 acceptNotwithstanding the
			 Act of March 8, 1922 (43 U.S.C. 912), the Secretary may accept the quitclaim,
			 disclaimer, and relinquishment by the Company of the right-of-way described in
			 subsection (c).
			(c)Description of
			 right-of-WayThe right-of-way
			 referred to in subsection (b) is the right-of-way within and adjacent to the
			 Pike National Forest in El Paso County, Colorado, that—
				(1)was originally granted by the Secretary to
			 the Company under the Act of March 3, 1875 (18 Stat. 482, chapter 152) for the
			 construction of a railroad and station in El Paso County, Colorado;
				(2)is located in the S½ sec. 6, T. 14 S., R.
			 67 W., and N½SE ¼ sec. 1, T. 14 S., R. 68 W., of the sixth principal meridian;
			 and
				(3)is depicted in a tracing filed as file
			 number 019416 in the United States Land Office at Pueblo, Colorado, on December
			 24, 1914.
				(d)Limited
			 ApplicabilityNothing in this
			 section affects the right, title, and interest of the Company in and to land
			 held in fee title by the Company.


		I
		112th CONGRESS
		1st Session
		H. R. 1353
		IN THE HOUSE OF REPRESENTATIVES

			April 4, 2011
			Mr. Murphy of
			 Connecticut introduced the following bill; which was referred to the
			 Committee on Energy and
			 Commerce

		A BILL
		To reinstate and transfer certain hydroelectric licenses
		  and extend the deadline for commencement of construction of certain
		  hydroelectric projects.

		1.Short titleThis Act may be cited as the
			 Collinsville Renewable Energy Promotion
			 Act.
		2.Reinstatement of
			 expired licenses and extension of time to commence construction of
			 ProjectsSubject to section 4
			 of this Act and notwithstanding the time period under section 13 of the Federal
			 Power Act (16 U.S.C. 806) that would otherwise apply to Federal Energy
			 Regulatory Commission projects numbered 10822 and 10823, the Commission
			 may—
			(1)reinstate the license for either or each of
			 those projects; and
			(2)extend for 2 years after the date on which
			 either or each project is reinstated under paragraph (1) the time period during
			 which the licensee is required to commence the construction of such
			 projects.
			3.Transfer of
			 licenses to the town of Canton, ConnecticutNotwithstanding section 8 of the Federal
			 Power Act (16 U.S.C. 801) or any other provision thereof, if the Commission
			 reinstates the license for, and extends the time period during which the
			 licensee is required to commence the construction of, a Federal Regulatory
			 Commission project under section 2, the Commission shall transfer such license
			 to the town of Canton, Connecticut.
		4.Environmental
			 assessment
			(a)DefinitionFor purposes of this section, the term
			 environmental assessment shall have the same meaning as is given
			 such term in regulations prescribed by the Council on Environmental Quality
			 that implement the National Environmental Policy Act of 1969 (42 U.S.C. 4321 et
			 seq.).
			(b)Environmental
			 assessmentNot later than 180
			 days after the date of enactment of this Act, the Federal Energy Regulatory
			 Commission (referred to in this Act as the Commission) shall
			 complete an environmental assessment for Federal Energy Regulatory Commission
			 projects numbered 10822 and 10823, updating, to the extent necessary, the
			 environmental analysis performed during the process of licensing such
			 projects.
			(c)Comment
			 periodUpon issuance of the
			 environmental assessment required under subsection (b), the Commission
			 shall—
				(1)initiate a 30-day
			 public comment period; and
				(2)before taking any
			 action under section 2 or 3—
					(A)consider any
			 comments received during such 30-day period; and
					(B)incorporate in the
			 license for the projects involved, such terms and conditions as the Commission
			 determines to be necessary, based on the environmental assessment performed and
			 comments received under this section.
					5.DeadlineNot later than 270 days after the date of
			 enactment of this Act, the Commission shall—
			(1)make a final
			 decision pursuant to paragraph (1) of section 2; and
			(2)if the Commission
			 decides to reinstate 1 or both of the licenses under such paragraph and extend
			 the corresponding deadline for commencement of construction under paragraph (2)
			 of such section, complete the action required under section 3.


110 HR 4333 IH: To direct the Secretary of the Interior to allow for

U.S. House of Representatives
2007-12-06
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

		I
		110th CONGRESS
		1st Session
		H. R. 4333
		IN THE HOUSE OF REPRESENTATIVES

			December 6, 2007
			Mr. Matheson
			 introduced the following bill; which was referred to the
			 Committee on Natural
			 Resources

		A BILL
		To direct the Secretary of the Interior to allow for
		  prepayment of repayment contracts between the United States and the Uintah
		  Water Conservancy District.

		1.Prepayment of certain
			 repayment contracts between the united states and the uintah water conservancy
			 districtThe Secretary shall
			 allow for prepayment of the repayment contract no. 6–05–01–00143 between the
			 United States and the Uintah Water Conservancy District dated June 3, 1976, and
			 supplemented and amended on November 1, 1985, and on December 30, 1992,
			 providing for repayment of municipal and industrial water delivery facilities
			 for which repayment is provided pursuant to such contract, under terms and
			 conditions similar to those used in implementing section 210 of the Central
			 Utah Project Completion Act (Public Law 102–575), as amended. The prepayment
			 may be provided in several installments to reflect substantial completion of
			 the delivery facilities being prepaid, shall be adjusted to conform to a final
			 cost allocation, and may not be adjusted on the basis of the type of prepayment
			 financing utilized by the District.


109 HR 2486 IH: Dietary Supplement Tax Fairness Act of 2005
U.S. House of Representatives
2005-05-19
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I
109th CONGRESS
1st Session
H. R. 2486
IN THE HOUSE OF REPRESENTATIVES

May 19, 2005
Mr. Burton of Indiana (for himself, Mr. Pallone, Mr. Paul, Mr. Terry, and Mr. Gerlach) introduced the following bill; which was referred to the Committee on Ways and Means

A BILL
To amend the Internal Revenue Code of 1986 to provide that amounts paid for foods for special dietary use, dietary supplements, or medical foods shall be treated as medical expenses.

1.Short titleThis Act shall be known as the Dietary Supplement Tax Fairness Act of 2005.
2.FindingsThe Congress finds that—
(1)the inclusion of foods for special dietary use, dietary supplements, and medical foods in the deduction for medical expenses does not subject such items to regulation as drugs,
(2)the Internal Revenue Code of 1986 treats such items as allowable for the medical expense deduction, but only if such items are prescribed drugs,
(3)such items have been shown through research and historical use to be a valuable benefit to human health, in particular disease prevention and overall good health, and
(4)children with inborn errors of metabolism, metabolic disorders, and autism, and all individuals with diabetes, autoimmune disorders, and chronic inflammatory conditions, frequently require daily dietary interventions as well as medical interventions to manage their conditions and such dietary interventions often become a significant economic burden on such individuals.
3.Amounts paid for foods for special dietary use, dietary supplements, or medical foods treated as medical expenses
(a)In generalParagraph (1) of section 213(d) of the Internal Revenue Code of 1986 (relating to medical, dental, etc., expenses) is amended by redesignating subparagraphs (C) and (D) as subparagraphs (D) and (E), respectively, and by inserting after subparagraph (B) the following new subparagraph:

(C)for foods for special dietary use, dietary supplements (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act), and medical foods,.
(b)Special rule for insurance covering foods for special dietary use, dietary supplements, and medical foodsSubsection (d) of section 213 of the Internal Revenue Code of 1986 (relating to medical, dental, etc., expenses) is amended by adding at the end the following new paragraph:

(12)Special rule for insurance covering foods for special dietary use, dietary supplements, and medical foodsAmounts paid for insurance covering foods and supplements referred to in paragraph (1)(C) shall be treated as described in paragraph (1)(E) only if such foods and supplements comply with applicable good manufacturing practices prescribed by the Food and Drug Administration or with other comparable standards..
(c)Conforming amendments
(1)Subparagraph (E) of section 213(d)(1) of the Internal Revenue Code of 1986, as redesignated by subsection (a), is amended by striking subparagraphs (A) and (B) and inserting subparagraphs (A), (B), and (C).
(2)The last sentence of section 213(d)(1) of such Code is amended by striking subparagraph (D) and inserting subparagraph (E).
(3)Paragraph (6) of section 213(d) of such Code is amended—
(A)by striking and (C) and inserting (C), and (D), and
(B)by striking paragraph (1)(D) in subparagraph (A) and inserting paragraph (1)(E).
(4)Paragraph (7) of section 213(d) of such Code is amended by striking and (C) and inserting (C), and (D).
(5)Sections 72(t)(2)(D)(i)(III) and 7702B(a)(4) of such Code are each amended by striking section 213(d)(1)(D) and inserting section 213(d)(1)(E).
(d)Effective dateThe amendments made by this section shall apply to taxable years beginning after the date of the enactment of this Act.